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Functional Analysis of RUNX2 Mutations in Japanese
Patients with Cleidocranial Dysplasia Demonstrates
Novel Genotype-Phenotype Correlations
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Toshio Miyawaki,1 Yoshiaki Ito,3 and Katsuya Shigesada2
1Department of Pediatrics, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan; and Departments
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Cleidocranial dysplasia (CCD) is an autosomal dominant heritable skeletal disease caused by heterozygousmutations
in the osteoblast-specific transcription factor RUNX2. We have performed mutational analysis of RUNX2 on 24
unrelated patients with CCD. In 17 patients, 16 distinct mutations were detected in the coding region of RUNX2:
4 frameshift, 3 nonsense, 6 missense, and 2 splicing mutations, in addition to 1 polymorphism. The missense
mutations were all clustered within the Runt domain, and their protein products were severely impaired in DNA
binding and transactivation. In contrast, two RUNX2 mutants had the Runt domain intact and remained partially
competent for transactivation. One criterion of CCD, short stature, was much milder in the patients with the intact
Runt domain than in those without. Furthermore, a significant correlation was found between short stature and
the number of supernumerary teeth. On the one hand, these genotype-phenotype correlations highlight a general,
quantitative dependency, by skeleto-dental developments, on the gene dosage of RUNX2, which has hitherto been
obscured by extreme clinical diversities of CCD; this gene-dosage effect is presumed to manifest on small reductions
in the total RUNX2 activity, by approximately one-fourth of the normal level at minimum. On the other hand,
the classic CCD phenotype, hypoplastic clavicles or open fontanelles, was invariably observed in all patients,
including those with normal height. Thus, the cleidocranial bone formation, as mediated by intramembranous
ossification, may require a higher level of RUNX2 than does skeletogenesis (mediated by endochondral ossification),
as well as odontogenesis (involving still different complex processes). Overall, these results suggest that CCD could
result from much smaller losses in the RUNX2 function than has been envisioned on the basis of the conventional
haploinsufficiency model.
Introduction
Cleidocranial dysplasia (CCD [MIM 119600]) is a dom-
inantly inherited autosomal bone disease that is char-
acterized by persistently open sutures or delayed closure
of sutures, hypoplastic or aplastic clavicles, short stature,
delayed eruption of permanent dentition, supernumer-
ary teeth, and other skeletal anomalies (Jarvis and Keats
1974). Considerable phenotypic variation has been re-
ported, even within families (Chitayat et al. 1992). The
phenotypic spectrum ranges from mildly affected indi-
viduals with mere dental abnormalities to severely af-
fected patients with generalized osteoporosis, although
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tooth anomalies and some degrees of clavicular hypopla-
sia seem to be consistent features of the disease (Mundlos
1999; Quack et al. 1999).
Recently, it has been established that CCD results
from heterozygous mutations or deletion of an osteo-
blast-specific transcription factor, core-binding factor
A1 (CBFA1), leading to the proposal that haploinsuf-
ficiency in CBFA1 is responsible for this disease (Lee et
al. 1997;Mundlos et al. 1997). Furthermore, a radiation-
induced mutant mouse that carries similarities to CCD
(Sillence et al. 1987) has also been demonstrated to con-
tain a deletion in one Cbfa1 allele (Otto et al. 1997).
CBFA1 (also variously called “PEBP2aA,” AML3,” or
“OSF2”) is one of the three mammalian genes that en-
code the a subunit of the heterodimeric transcription
factor PEBP2/CBF (Ogawa et al. 1993b; Levanon et al.
1994; Ducy et al. 1997). PEBP2/CBF is composed of two
structurally unrelated subunits, a and b (Kamachi et al.
1990). The a subunit is characterized by a highly con-
served 128-amino-acid region termed the “Runtdomain”
(Kagoshima et al. 1993), which shares a high degree of
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homology with the products of the Drosophila genes
runt (Kania et al. 1990) and lozenge (Daga et al. 1996).
Herein, we refer to this gene as “RUNX2” (GenBank
accession number AF001450), according to the re-
cently introduced standard naming for the mammalian
runt-related genes. The other two a-subunit–encoding
genes are RUNX1/AML1/PEBP2aB/CBFA2 (Miyoshi
et al. 1991; Bae et al. 1993) and RUNX3/PEBP2aC/
AML2/CBFA3 (Levanon et al. 1994; Bae et al. 1995;
Wijmenga et al. 1995). Mouse knockout models have
demonstrated that these three genes have indispensable
roles in the master regulation of distinct developmental
pathways: Runx1, for definitive hematopoiesis (Okuda
et al. 1996; Q. Wang et al. 1996a); Runx2, for oste-
ogenesis (Komori et al. 1997; Otto et al. 1997); and
Runx3, for gastrointestinal organogenesis and func-
tion (Li et al. 2002). In contrast, only one gene is
known to encode the mammalian b subunit, termed
“PEBP2b/CBFb” (designated “PEBP2b” hereafter)
(Ogawa et al. 1993a; S. Wang et al. 1993). Although
PEBP2b can heterodimerize with all three RUNX para-
logs, until very recently, its biological significance has
been shown only for RUNX1. Homozygous disruption
of PEBP2b in mice completely blocked definitive he-
matopoiesis in a manner virtually identical to that ob-
served with RUNX1 knockout mice, but their premature
death in utero made it difficult to investigate potential
alterations in other late-developing processes (Sasaki et
al. 1996; Q. Wang et al. 1996b). However, PEBP2b has
also proved to be essential at least for osteogenesis by
the recent convergent demonstrations, from three dif-
ferent laboratories, that its conditional or partial defi-
ciency in mice causes severe bone defects that are similar
to Ccd (Yoshida et al., in press).
The Runt domain is responsible for DNA binding and
heterodimerization with the b subunit (Kagoshima et al.
1993). The Runt domain also contains a nuclear-locali-
zation signal (NLS) on its C-terminal border (T. Kanno
et al. 1998). The C-terminus of RUNX2 is a region rich
in proline, serine, and threonine, which are necessary for
RUNX2-mediated transcriptional regulation and are in-
volved in functional interactions with various other tran-
scription factors, coactivators, and corepressors.
The b subunit does not bind to DNA but allosterically
enhances DNA binding by the a subunit (Ogawa et al.
1993b; Kagoshima et al. 1996; Tahirov et al. 2001). Re-
cently, PEBP2b has been found to have another impor-
tant role in the protection of the a subunit from intra-
cellular proteolytic degradation mediated by the ubiqui-
tin-proteasome system (Huang et al. 2001). Within cells,
PEBP2b itself is localized in the cytoplasm and can enter
the nucleus only through association with Runx proteins.
Notably, however, the nuclear colocalization of PEBP2b
with Runx proteins is normally regulated to proceed
only partly, supposedly because the Runt domain is large-
ly masked by its intramolecular interactions with regions
N- or C-terminal of the Runt domain (Lu et al. 1995; T.
Kanno et al. 1998; Y. Kanno et al. 1998; Kim et al. 1999).
Nevertheless, this intramolecular masking can be relieved
when the N- or C-terminal region flanking the Runt do-
main is truncated artificially or is replaced with foreign
sequences, as seen in leukemia-associated chimeric prod-
ucts of RUNX1 such as AML1-ETO and AML1-Evi1,
or when PEBP2b is altered to gain an increased ability
to heterodimerize with Runx1 again, as seen in its leu-
kemia-associated chimeric product, CBFb-SMMHC (Lu
et al. 1995; Adya et al. 1998; T. Kanno et al. 1998; Y.
Kanno et al. 1998; Tanaka et al. 1998). Thus, mutation-
mediated perturbations in the intracellular interactionbe-
tween PEBP2b and RUNX2 have been regarded to have
important pathogenic implications.
The haploinsufficiency model for CCD implies that
bone formation is highly sensitive to the gene dosage
of RUNX2. As a matter of fact, the regulatory impor-
tance of gene dosage is a common theme across most
Runt-family proteins. The earliest known precedent is
the Drosophila gene runt, which contributes to sex de-
termination in a dosage-dependent manner (Duffy and
Gergen 1991). Another more recent example is the as-
sociation between RUNX1 and a human blood disease
called “familial platelet disorder with predisposition to
acute myelogenous leukemia” (FPD/AML1). In a close
analogy to CCD, FPD/AML, as well as some sporadic
cases of leukemias, has been shown to be due to hap-
loinsufficiency in RUNX1—caused by its heterozygous
mutation (Osato et al. 1999; Song et al. 1999).
Recently, additional cases of heterozygous mutation
in RUNX2 have been identified in nearly 60 families
with CCD, including both familial and sporadic cases
(Quack et al. 1999; Zhou et al. 1999; Golan et al. 2000;
Yokozeki et al. 2000; Zhang et al. 2000; Yamachika et
al. 2001; for review, see Otto et al. 2002). Despite these
accumulating mutational data, it has largely remained
obscure exactly what range and extent of functional loss
could be conferred by the various mutations identified
and also how such putative diversities in mutational
effects would be correlated with the phenotypic varia-
bility of CCD. To address these questions, we have per-
formed screening and detailed functional analyses of
RUNX2 mutations in 24 Japanese patients with CCD.
We describe herein the results of these analyses and
some novel genotype-phenotype correlations revealed
therefrom. Although preliminary information from this
study has frequently been quoted in several previous
articles (Nagata et al. 1999; Werner et al. 1999; Warren
et al. 2000; Bravo et al. 2001; Nagata andWerner 2001;
Tahirov et al. 2001; Otto et al. 2002), the present report
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provides the first full account of our results, with cor-
rections to earlier quotations in a few important details.
Patients, Material, and Methods
Patients
Twenty-four unrelated families with the clinical di-
agnosis of CCD (for review of diagnostic criteria, see
Mundlos 1999) were investigated in the present study.
Informed consent was obtained from all individuals.
Genomic DNA and RNA were prepared from blood
lymphocytes by standard procedures.
Mutation Detection
Exons 1–7 of theRUNX2 gene were amplified by PCR
under standard conditions. The primers used for ge-
nomic PCR amplification and sequencing have been de-
scribed elsewhere (Zhang et al. 2000). The amplification
products were checked by agarose gel electrophoresis.
For SSCP, PCR products were added to 5 ml of sample
buffer, were denatured at 95C for 5 min, and were
applied to the gel (GeneGel Excel 12.5/24Kit; Pharmacia
Biotech). After electrophoresis, PCR products were vi-
sualized by silver staining, and those showing altered
mobilities were selected and sequenced using Big Dye
Terminator on an ABI310 automated sequencer (PE
Biosystems). Every mutation was confirmed by sequenc-
ing of the products from several independent PCRs. To
determine exon 3 skipping in patient 17, RT-PCR was
performed as described elsewhere (Zhang et al. 2000).
In patient 15, RT-PCR was done with primers 5′-TCA-
GATTACAGACCCCAGGC-3′ (sense) and 5′-TCTCAG-
TGAGGGATGAAATG-3′ (antisense). The product was
cloned into the pCRII TA cloning vector (Invitrogen)
and was sequenced.
Plasmids and Mutagenesis
For expression of the Runt domain–containing frag-
ment as a fusion N-terminally tagged with hexahisti-
dines, the nucleotide sequences for amino acids 74–273
of human RUNX2were cloned in frame into the BamHI
and PstI sites of the pQE9 vector (Qiagen). RUNX2
mutations were introduced into this construct by site-
directed mutagenesis through use of PCR. The integrity
of all the PCR constructs was confirmed by sequencing.
Electrophoretic Mobility Shift Assay (EMSA)
The hexahistidine-tagged Runt domain was expressed
in Escherichia coli, was purified in a nickel nitrilotriacetic
resin (Ni-NTA) (Qiagen), andwas subjected to EMSAwith
a probe carrying a polyomavirus enhancer-derived PEBP2
site, essentially as described elsewhere (Kagoshima et al.
1996). Expression and purification of the PEBP2b protein
has been described elsewhere (Ogawa et al. 1993a).
Affinity Assay of RUNX2-PEBP2b Association
The hexahistidine-tagged RUNX2 fragment (10 mg)
was incubated with tagless PEBP2b (5 mg) and a Ni-
NTA resin. The resin was successively washed with buf-
fers containing 16 mmol/liter and was eluted with 250
mmol/liter imidazole. Proteins in each fraction were an-
alyzed by SDS-PAGE followed by staining with Coomas-
sie brilliant blue.
Transcriptional Assay
For in vivo functional studies of mutant RUNX2 pro-
teins, the NotI-HindIII fragments from pQE9-RUNX2
(eight mutants in the Runt domain) were substituted into
the compatible sites of pEF-RUNX2 (sites 1–507) (Zhang
et al. 2000). For Q266X, the NotI-Tth111I fragments
from pQE9-RUNX2 were substituted into the compat-
ible sites of pEF-RUNX2 (sites 1–507). The remaining
mutants were constructed by site-directed mutagenesis.
NIH3T3 cells were maintained in Dulbecco modified
Eagle medium supplemented with 10% (v/v) fetal bovine
serum. For the luciferase assay, NIH3T3 cells seeded into
six-well plates were transfected by using the nonliposomal
transfection reagent FuGENE 6 (Boehringer Mannheim).
The luciferase-reporter plasmid wild-type 1050.rOC-luc
(Towler et al. 1994; Javed et al. 1999) (0.5 mg), the effector
plasmid pEF-RUNX2 (1-507) (0.5 mg) containing mu-
tation, and pEF-PEBP2b2 (0.2 mg) were transfected into
NIH3T3 cells by using FuGENE 6. As an internal con-
trol, 1 ng of pEF-RL luciferase reporter also was includ-
ed. On the one hand, to avoid an excessive production
of RUNX2, we adjusted the amount of pEF-RUNX2 to
slightly less (80%) than minimally saturating level (0.6
mg), as determined by prior titration experiments. On
the other hand, PEBP2b2 was used at an oversaturating
dose. Cells were harvested 24 h after transfection, and
luciferase activities were determined by the Dual-Lucif-
erase Reporter Assay System (Promega) in a luminome-
ter. Firefly luciferase activities were normalized byRenil-
la luciferase activities. All transfection experiments were
done at least three times.
Subcellular Localization
The pEF-RUNX2 plasmids bearing wild type and mu-
tant were transfected into NIH3T3 cells by using the Fu-
GENE 6 reagent. Immunofluorescence labeling ofRUNX2
and PEBP2b were performed as described elsewhere (Lu
et al. 1995), by using mouse anti-PEBP2aA, fluorescein
isothiocyanate–conjugated goat anti-mouse immuno-
globulin G (IgG), rabbit anti-PEBP2b, and Texas Red–
conjugated AffiniPure Donkey anti-Rabbit IgG. The cells
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were visualized and photographed with a fluorescent
microscope.
Statistical Analysis
Statistical analysis of present height SD scores was
performed on 31 patients. The height was evaluated
by the longitudinal growth standards for the Japa-
nese. The height SD score between the Runt domain–
impaired group (15 families; 27 patients) and the Runt
domain–intact group (2 families; 4 patients) were com-
pared using the Mann-Whitney test. The difference
between the two groups was accepted as significant
at . The Kruskal-Wallis H test was performed,P ! .01
to compare three groups of clavicle phenotypes. Cor-
relation between the number of supernumerary teeth
and height was evaluated with the Spearman corre-
lation in nine patients.
Results
Clinical Data
Twenty-four unrelated Japanese families with clinical
diagnosis of CCD were included in the present study
(table 1). The patient group contained both male and
female patients, in approximately equal proportions,
ranging in age from 0 to 30 years, with a median of 2
years. Of the 24 families, 9 (37.5%) represented spo-
radic cases. A CCD phenotype was defined by the pres-
ence of hypoplastic clavicles and delayed closure of the
anterior fontanelle in addition to the observation of
classic craniofacial features. Although dental anomalies
were not included as a fixed criterion because of their
age-related penetrance, this feature was consistently
observed in older patients. Stature was found to be
significantly reduced in both male and female patients
with CCD, in agreement with previous observation (Jen-
sen 1990).
Identification of Heterozygous Mutations in RUNX2
Among the 24 families examined, we were able to de-
tect a total of 15 heterozygous mutations and 1 additional
polymorphism in 17 patients (table 1 and fig. 1). Of these
mutations, 11 are novel, and the other 5 have been re-
ported previously (Quack et al. 1999; Zhou et al. 1999;
Zhang et al. 2000). In the remaining seven patients, no
mutation was detected by the SSCP method combined
with direct sequencing. In four of these patients, we also
searched for larger chromosomal deletions in theRUNX2
gene, by Southern blotting of genomic DNA with human
RUNX2 cDNA as a probe; however, no such deletion
was detected (data not shown). The other three patients
were not analyzed, because the DNA material was in-
accessible. The mutations thus identified can be classified
into five groups, according to their effects on the final
protein coding frame, as follows:
Missense mutations.—Six missense mutations were
detected in seven patients. Of these mutations, two
(612ArT [K204N] and 617CrT [T206I]) were nov-
el, and the other four (526CrT [R176W], 548TrC
[F183S], 631CrT [R211W], and 632GrA [R211Q])
have been described previously. Notably, R211W was
shared by two unrelated de novo patients in the pres-
ent study. All missense mutations were located within
the Runt domain, reconfirming the general trend ob-
served previously (Quack et al. 1999; Zhou et al. 1999).
Nonsense mutations.—Nonsense mutations were
detected in three patients. Of these mutations, two
(154CrT [Q52X] and 793CrT [Q266X]) were novel,
and the third (535CrT [R179X]) has been reported
previously (Quack et al. 1999).
Frameshift mutations.—Four frameshift mutations
were identified in five patients. Of these mutations,
three were simply due to single-base deletions
(136delC [46fs] and 453delT [151fs]) and a four-base
insertion (92insCGGT [31fs]), respectively; notably,
453delT recurred in two unrelated de novo patients.
The fourth mutation was caused by a single-base sub-
stitution, 1043CrT, which was initially supposed to
cause a missense mutation, A348V, and was described
as such in the recent review by Otto et al. (2002).
However, this mutation simultaneously generated a
new alternative splice-donor site within exon 6 at the
position 4 bases upstream from the normal donor site
(fig. 2a). RT-PCR analysis revealed that this new do-
nor site was predominantly used in place of the nor-
mal one, resulting in a frameshift after Q347.
Exon-skipping mutations.—Two mutations were de-
tected on the boundary between exon 3 and intron 3 (fig.
2b). In one of them, a 4-nt deletion (IVS33delAAGT)
had taken place within the splice-donor signal at the
boundary between exon 3 and intron 3 (AAGTAAGT),
resulting in a less optimal donor site in which the canon-
ical GTmotif was followed by an unfavorable pyrimidine-
rich segment (AAGTACTC). RT-PCR analysis on RNA
from the patient revealed that this mutation ultimately
led to an in-frame skipping of exon 3 as a whole (amino
acids 190–214), rather than to a simple inactivation of
that donor site alone. The other mutation, IVS32TrC,
directly hit the invariant GT signal at the same splice
donor site. Although RT-PCR analysis could not be per-
formed in this case, the mutation is also supposed to result
in skipping of exon 3. In fact, an analogous mutation of
GTrTT in RUNX2 has been reported to elicit the skip-
ping of exon 3 for two independent cases of CCD (Zhou
et al. 1999; Zhang et al. 2000).
Polymorphism.—One novel polymorphism, 510TrC
(D170, synonymous), was found within exon 2 on one
allele in one patient, whose healthy mother carried the
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Figure 1 Schematic representation of RUNX2, showing the localization of mutations in patients with CCD. The seven exons of RUNX2
are represented by boxes, and introns are represented by lines; hatched boxes indicate the Runt domain. The mutations identified in the present
study and previous studies are indicated above and below the diagrammatic structure ofRUNX2 (the 507-amino-acid isoformstartingwithMRIPVD).
Figure 2 Sequence analysis of splicing mutations. A, Point mu-
tation with eventual 4-base skipping in patient 15. The boundary se-
quences of exons 6 and 7 in the wild-type cDNA are shown in the
lower boxes. The mutated nucleotide is underlined and annotated as
indicated by arrows. The resultant cDNA sequence causing frameshift
is shown in the upper box. B, Exon-skipping mutations found in pa-
tients 16 and 17. The boundary sequences of exons 2–4 in the wild-
type cDNA are shown in the lower boxes. The mutated nucleotide(s)
at the upstream boundary of intron 3 are underlined and annotated
as indicated by arrows. The resultant cDNA sequence lacking exon 3
is shown in the upper box. RT-PCR was performed as described else-
where (Zhang et al. 2000). Wt p wild type.
same mutation on both alleles. Incidentally, this patient
also possessed one of the aforementioned nonsense mu-
tations, Q266X, which was supposed to be responsible
for CCD.
Mutational Effects on Runt Domain Function
To examine mutational effects on Runt domain func-
tion, we overproduced partial RUNX2 proteins (amino
acids 74–273 for the wild type and 8 mutants) in E. coli
and subjected them to EMSA (fig. 3a). In this assay, the
DNA-binding and heterodimerization activities can
readily be detected by shifting and supershifting of the
DNA band in the absence and presence, respectively, of
PEBP2b, as typically seen with the wild type (fig. 3a, Wt
 and , respectively). Of the eight mutants tested
(151fs, R179X, R176W, K204N, T206I, R211W, and
R211Q), all but F183S showed no DNA binding, re-
gardless of the presence or absence of PEBP2b. F183S
gave a barely visible supershifted band in a PEBP2b-
dependent manner, suggesting that it retained the het-
erodimerization activity together with a trace potential
for DNA binding. The six missense mutants were further
tested for the heterodimerization ability by an affinity
assay (fig. 3b). They were all capable of binding to
PEBP2b as proficiently as the wild type. Thus, the pre-
vious supposition that F183S would induce a global
change in protein conformation (Bravo et al. 2001; Na-
gata and Werner 2001; Tahirov et al. 2001; Otto et al.
2002) has to be amended.
Transcription Activation Abilities of the RUNX2
Mutants
We measured the transactivation potential of the
mutant RUNX2 proteins, using a reporter construct
based on the rat osteocalcin promoter, which has been
well characterized as an osteoblast-specific target of
RUNX2 (Geoffroy et al. 1995; Merriman et al. 1995;
Zhang et al. 2000). With NIH3T3 cells as host, the
transfection of the wild-type RUNX2 at a near-op-
timal dose together with a saturating amount of
PEBP2b effected a strong transactivation up to ∼20-
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Figure 3 Mutational alterations in DNA-binding and heterodimerization activities of the Runt domain. b p PEBP2b; Wt p wild type.
a, Partial RUNX2 proteins (indicated at top) produced in E. coli and subjected to EMSA. The “” and “” symbols signify the presence and
absence, respectively, of PEBP2b. b, Partial RUNX2 proteins subjected to affinity assay. A p input RUNX2 protein; W p unbound proteins
in the third wash; E p bound proteins eluted at 250 mmol/liter imidazole.
Figure 4 Transactivation of the osteocalcin promoter by ex-
ogenously expressed RUNX2 proteins in NIH3T3 cells. Cells were
transfected with a reporter plasmid (0.5 mg), indicated RUNX2 ex-
pression constructs (0.5 mg), and PEBP2b (0.2 mg). Luciferase activities
were measured and presented as the fold increase relative to the control
mock-transfected with the backbone expression vector. The mean val-
ues from three separate measurements are given with SDs (thin vertical
bars). Results obtained with and without coexpression of PEBP2b are
denoted by solid and shaded bars, respectively. WT p wild type.
fold over the mock-transfected control. Note here that
a much weaker transcriptional stimulation was ob-
served without coexpression of PEBP2b (fig. 4, cf.
shaded bar vs. solid bar marked “WT”). This indicates
that endogenous PEBP2b in NIH3T3 is limiting for the
RUNX2-dependent transcription and that the coex-
pressed RUNX2 and PEBP2b can intracellularly inter-
act with each other in a productive manner. Of the
mutants tested, those impaired in the Runt domain dis-
played either no transactivation activity or markedly
reduced transactivation activities, showing good par-
allelism with their impaired DNA binding. Notable in
particular is F183S, which retained a low but still sub-
stantial activity, as though reflecting its cryptic DNA-
binding potential noted above. In contrast, Q266X and
348fs, the two mutants that have the intact Runt do-
main and part of the C-terminal region, showed even
higher residual transactivation abilities that amount to
nearly half the normal level (fig. 4).
Subcellular Localization of the RUNX2 Mutants
RUNX proteins, in general, have an NLS at the C-
terminal border of the Runt domain (amino acids
204–220 in RUNX2 [KVTVDGPREPRREHRQKL])
(T. Kanno et al. 1998). They also promote nuclear
cotranslocation of PEBP2b, which has no NLS ele-
ment and tends to show cytoplasmic localization on
its own (Lu et al. 1995). For the examination of
whether the mutant RUNX2 proteins were affected in
these nuclear-localization functions, they were over-
expressed in NIH3T3 cells and were visualized by im-
munostaining. So far, 10 mutants have been tested,
with the exception of those that either terminate
before the Runt domain or involve exon skipping,
which were obviously supposed to lack the nuclear-
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Figure 5 Subcellular localization of RUNX2. The indicated RUNX2 proteins were overexpressed in NIH3T3 cells and were made visible
by immunofluorescence staining with an anti-PEBP2aA antibody: wild type (a), R176W (b), F183S (c), Q266X (d), 348fs (e), 151fs (f), R179X
(g), K204N (h), T206I (i), R211Q (j), and R211W (k). For each mutant, at least 100 well-stained cells were counted and were classified into
a few subpopulations according to their pattern of staining. A typical image of each distinct subpopulation is presented together with its fractional
percentage.
localization potential. The wild-type RUNX2 showed
a clear nuclear-localization pattern with exclusion
from the nucleoli in virtually every cell stained sig-
nificantly (fig. 5a). In contrast, the RUNX2 mutants
all exhibited altered subcellular localization with vary-
ing degrees and patterns regardless of the presence
or absence of the intact NLS. Most mutants (R176W,
F183S, T206I, R211Q, R211W, 151fs, Q266X, and
348fs) showed nonuniform distributions: nuclear lo-
calization in 30%–50% of the observed cells and dual
localization to both the cytoplasm and the nucleus in
the remaining 50%–70% (figs. 5b–5f and 5i–5k).
Among the mutants impaired in the NLS, only K204N
and R179X were completely localized in the cyto-
plasm (figs. 5g and 5h). Overall, these results are con-
sistent with the previous proposal that the nuclear
accumulation of the RUNX2 protein depends on the
interplay between multiple nuclear-localization ele-
ments spread over the Runt domain and the C-ter-
minal region (Lu et al. 1995; for more details, see
the “Discussion” section). Furthermore, the mutants
that show cytoplasmic localization produced speck-
led staining patterns in the cytoplasm in virtually all
cases, except that the two nonsense mutants (R179X
and Q266X) were stained diffusely in the cytoplasm
(figs. 5d and 5g).
For the further examination of mutational effects on
the subcellular localization of PEBP2b, RUNX2 and
PEBP2b were coexpressed in NIH3T3 cells and were
subjected to double immunofluorescent staining with an-
tibodies specific to the respective proteins. In the control
experiment, the wild-type RUNX2 and PEBP2b showed
quite different distribution patterns. Whereas RUNX2
was almost completely localized to the nucleus, PEBP2b
was distributed in both the cytoplasm and the nucleus,
although it was visibly more abundant in the former
than in the latter (figs. 6a and 6c). This reconfirmed the
earlier observations that the wild-type RUNX2 and also
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Figure 6 Colocalization of RUNX2 and PEBP2b. PEBP2b was
coexpressed with either the wild-type RUNX2 (a and c) or T206I
RUNX2 (b and d) in NIH3T3 cells, and the two subunits were visualized
by double staining with anti-RUNX and anti-b antibodies, respectively.
a, Wild-type RUNX2. b, T206I RUNX2. c, PEBP2b coexpressed with
wild-type RUNX2. d, PEBP2b coexpressed with T206I RUNX2.
RUNX1 displayed only a limited capacity to colocalize
PEBP2b, at least under the coexpression regimen em-
ployed (Lu et al. 1995; Y. Kanno et al. 1998; Tanaka et
al. 1998). In contrast, T206I and PEBP2b were colo-
calized in both the cytoplasm and the nucleus, showing
almost identical patterns as characterized by bright cy-
toplasmic speckles and nucleoli-like dark spots that
punctuated low diffuse backgrounds (figs. 6b and 6d).
This speckled pattern is very similar to that observed
when T206I was expressed alone. Thus, the mutant
RUNX2 protein accumulated in the aberrant cytoplas-
mic speckles must retain a high heterodimerization ac-
tivity and hence could avidly sequester PEBP2b therein.
Genotype-Phenotype Correlation
Taking into account the result of transactivation
analysis, we compared the various phenotypes of CCD
between two groups of patients that were clustered ac-
cording to whether the Runt domain was or was not
mutationally impaired. A significant difference was
found for the height SD score, whose mean value was
much lower in the impaired group of 27 patients
(2.56) than in the intact group of 4 patients (0.55)
(fig. 7a). As an apparent deviation from this correla-
tion, one patient (151fs with 47,XXX [●1 in fig. 7])
in the Runt domain–impaired group showed a nearly
normal physical growth (0.5), whereas the other fe-
male patient with the same mutation having a normal
karyotype (46,XX [● in fig. 7]) had a very severe short
stature (4.04). However, it is known that the standard
height of female patients with the 47,XXX karyotype
is higher than that of the unaffected control individual,
owing to the presence of SHOX (short stature homeo-
box-containing gene) on the X chromosome (Ogata et al.
2001). Thus, it is possible that an overdosage of SHOX
masked the growth-retarding effect due to mutation
151fs in this particular patient (fig. 7a).
Prompted by the preceding result, we further compared
the height SD score with other functional and phenotypic
parameters. No recognizable correlation was observed
with the classic CCD phenotype, cranial and clavicular
anomalies (figs. 7b and 7c). However, a remarkable cor-
relation was found between the height SD score and the
transactivation potential of RUNX2 mutants (fig. 8). The
regression curve suggests that the skeletal growth begins
to deteriorate when the RUNX2 activity from one allele
goes down just by one-half and undergoes accelerated
worsening with its further loss. In addition, another in-
triguing correlation was demonstrated between the height
SD score and the number of supernumerary teeth (fig. 9).
Note that all the data points fit a linear regression curve
with surprisingly small deviations. This implies an inher-
ent mechanistic commonality between the skeletal growth
and the dental development in their dependencies on the
RUNX2 activity, despite the tremendous apparent dissim-
ilarities of these two organogenic processes.
Discussion
In the present study, we have identified 15 nonpoly-
morphic mutations in 17 unrelated families with CCD
in Japan. Of these mutations, 10 are novel, and 5 have
previously been reported for multiple cases. Detailed
functional analyses of these mutations have provided
novel insights into various critical issues, ranging from
the structure-function relationships of RUNX2 to the
genotype-phenotype correlation of CCD.
Among the mutations identified, missense mutations
were exclusively clustered within the Runt domain, re-
confirming previous reports (Quack et al. 1999; Zhou
et al. 1999; Zhang et al. 2000). In contrast, other types
of mutations that cause premature terminations or in-
ternal deletions/insertions were widely scattered over
the entire protein sequence. This extreme bias in the
distribution of missense mutations is taken to indicate
that the function of the Runt domain with its highly
conserved sequence is very susceptible to single-amino-
acid changes, whereas the less-well-conserved N- and
C-terminal regions are functionally more robust and
require larger structural changes for their pathogeni-
cally significant alterations. Indeed, the Runt domain
that carries each missense mutation was severely im-
paired in DNA binding and hence also in transactiva-
tion. The observed mutational effects on Runt domain
function are consistent with and further serve to com-
plement the information provided by recent nuclear-
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Figure 7 Comparison of height SD scores between groups of patients with different genotypes or phenotypic variations.  p Void;
● p impaired in the Runt domain;  p intact in the Runt domain; ●1 p 151fs with 47,XXX; ● p 151fs with 46,XX. a, Mutational
effects on the Runt domain, impaired ( ) and intact ( ) ( ). b, Fontanelles, normal (none) and delayed ( ). c, Clavicles.np 27 np 4 P ! .01 np 16
AA p aplastic on both sides ( ); AH p aplastic on one side and hyopoplastic on the other side ( ); HH p hypoplastic on bothnp 4 np 3
sides ( ).np 16
Figure 8 Correlation between height SD score and transacti-
vation ability of each RUNX2 mutant (% wild-type control), as de-
termined in figure 4 ( ; ; ). Symbols are as de-np 16 rp 0.71 P ! .01
fined in figure 7.
magnetic-resonance and x-ray crystallographic analyses
of the Runt domain (Bravo et al. 2001; Nagata and
Werner 2001; Tahirov et al. 2001). In contrast, the
two nonsense or frameshift mutations located within
the C-terminal region retained substantial transacti-
vation potentials.
When the mutations identified in both the present
study and previous studies are compared, several posi-
tions emerge as mutational hotspots (fig. 1) (Otto et al.
2002). Of these, most conspicuous are the four arginine
residues: R211 (eight times), R176 and R179 (five times
each), and R377 (three times). Coincidentally, these ar-
ginine residues are all encoded by a CGA or CGG codon,
which should be particularly prone to mutagenic events
through a CpG-directed methylation of C followed by
deamination (Quack et al. 1999). Consistent with this
supposition, no mutation has ever been identified for an
AGA-encoded arginine, R214, even though this residue
is directly involved in DNA binding, as is R211. More-
over, a converse situation occurs in RUNX1, in which
recurrent mutations have been reported for the R214-
equivalent residue encoded by CGA, whereas no muta-
tion has been detected at the R179-equivalent residue
encoded by AGA (Osato et al. 1999; Song et al. 1999;
Preudhomme et al. 2000). Taken together, these obser-
vations suggest that the mutation rate of arginine is def-
initely facilitated, plausibly by one order of magnitude
(or more), when its codon contains CpG. A lesson from
these statistical considerations is that mutational screen-
ing on RUNX2 is still far from saturation, except for the
aforementioned hotspots, even though a total of nearly
80 cases have so far been identified. This warrants further
systematic mutational screening, by which more novel
mutations will be identified to enrich our insights into
the molecular basis for pathogenesis of CCD.
The RUNX2 mutants identified in the present study
also affected additional important functions—in partic-
ular, the abilities to mediate the nuclear localization of
RUNX2 itself, as well as of the partner subunit, PEBP2b.
This finding may merit keen attention, since it makes
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Figure 9 Correlation between number of supernumerary teeth
and height SD score ( ; ; ). Symbols are asnp 9 rp 0.96 P ! .0005
defined in figure 7.
an interesting parallel to the recurrent theme of per-
turbed intracellular interplay between RUNX1 and
PEBP2b as incurred by leukemia-associated chromo-
somal rearrangements involving the genes that encode
the respective proteins (Lu et al. 1995; Adya et al. 1998;
T. Kanno et al. 1998; Y. Kanno et al. 1998; Tanaka et
al. 1998). Enigmatically, themutants showed surprisingly
complex responses regardless of the presence or absence
of the intact NLS, causing variable localizations in either
the nucleus or the cytoplasm, from cell to cell in most
cases—with the exceptions of R179X and K204N,
which displayed cytoplasmic localization in all cells. An
additional strange feature found here is the occurrence
of cytoplasmic speckles in substantial fractions of cells
transfected with most RUNX2 mutants except the two
nonsense mutants, R179X and Q266X. One may won-
der whether these anomalies simply represent artifactual
cellular responses to overproduction ofmutant proteins.
However, it should be emphasized that the wild-type
RUNX2 never showed such aberrant distribution pat-
terns, not even when their expression vector was trans-
fected at oversaturating doses during our preliminary
titration experiments (data not shown). Conversely,
moreover, mutant RUNX2 invariably showed altered
subcellular distributions in nearly constant fractions of
visibly stained cells when they were expressed at much
lower dosages than that used in the standard assay.
Thus, we may reason that some intrinsic molecular or
functional properties unique to mutant proteins should
be responsible for their aberrant behaviors. Notable in
this regard is the previous deletion analysis (Lu et al.
1995), which has suggested that Runx2 contains ad-
ditional elements that promote nuclear localization as
coarsely mapped to the N-proximal half of the Runt
domain (positions 93–158) and the C-terminal region
spanning amino acids 272–502, in addition to the best-
characterized NLS on the C-terminal border of the Runt
domain (T. Kanno et al. 1998). A mutational change in
one or more of these elements would cause reduced
nuclear-localization potential to some extent, but total
inhibition would seldom result unless all of them should
be physically destroyed or conformationally perturbed.
An additional strange feature found in the above anal-
ysis is the occurrence of cytoplasmic speckles in sub-
stantial fractions of cells transfected with most RUNX2
mutants except the two nonsense mutants, R179X and
Q266X. Furthermore, the double-staining analysis re-
vealed that PEBP2b was colocalized with the T206I
RUNX2—and probably other mutants as well—in
those cytoplasmic speckles. Of interest, a very similar
observation has also been made with missense mutants
of RUNX1 that are associated with leukemias (Michaud
et al. 2002). Thus, the mutation-induced cytoplasmic
colocalization of RUNX proteins and PEBP2b could
have a general pathogenic significance. One attractive
possibility may be sequestration of PEBP2b away from
the normal RUNX protein encoded by the single resid-
ual wild-type allele (Michaud et al. 2002). Since PEBP2b
acts in the protection of RUNX proteins from ubiquitin-
proteasome–mediated proteolytic degradation (Huang
et al. 2001), its sequestration may lead to the more-
enhanced reduction of the residual RUNX2 activity. Ac-
cordingly, RUNX mutants would have more-severe del-
eterious effects when they retain the heterodimerization
activity than they otherwise would. This may be the
reason why missense RUNX mutations predictably af-
fecting heterodimerization have scarcely been detected
thus far—with only three found in RUNX2 (Quack et
al. 1999; Zhou et al. 1999; Otto et al. 2002) and none
found in RUNX1. In fact, one such mutant, T176A
(T200A in the original notation), was reported to have
only mild effects on the transactivation potential and
the CCD phenotype (Zhou et al. 1999).
Themost crucial question remaining is how the various
functional defects conferred byRUNX2mutationswould
correlate with the CCD phenotype. On the one hand, the
classic CCD phenotype, hypoplastic clavicles and open
sutures, was observed in virtually all patients examined.
On the other hand, skeletal and dental features, as rep-
resented by short stature and supernumerary teeth, re-
spectively, showed significant differences, depending on
whether the Runt domain was impaired (figs. 7a and 9)
and, in more quantitative terms, on how much residual
transactivation potential remained in mutant RUNX2
proteins (fig. 8). By a simple extrapolation of this cor-
relation, the RUNX2 activity in heterozygously affected
cells relative to the normal level would be reduced by
approximately one-fourth in the Runt domain–intact
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group and by approximately one-half in the Runt do-
main–impaired group. This means that the skeletal
growth and the dental development could readily and
proportionally be affected by such fractional changes in
the RUNX2 activity. By this line of reasoning,we suppose
that the omnipresent cleidocranial phenotype must be
even more sensitive to the RUNX2 deficiency. In other
words, the cleidocranial bone formation, which is me-
diated by intramembranous ossification, may require a
higher level of RUNX2 than does the skeletal bone for-
mation as mediated by intrachondral ossification. Unlike
the skeleto-dental phenotype, however, the cleidocranial
phenotype was extremely variable in pattern and severity
either between or within individual families, thereby
thwarting attempts to find any further genotype-phe-
notype correlation. This discrepancy may reflect a pos-
sible difference between these twodistinct osteogenicpro-
cesses in their sensitivities to genetic backgrounds other
than RUNX, or in fluctuations of developmental and
physiological conditions among individuals. The impor-
tance of genetic backgroundswas exemplified for the case
of skeletal growth by the observation that the short stat-
ure phenotype due to mutation 151fs was much milder
in one female patient with a 47,XXX karyotype than in
the corresponding patient with a normal karyotype.
To make an apparent contrast to human patients with
CCD, mice carrying one Runx2 null allele have been
reported to develop to normal size and to have no su-
pernumerary teeth, although they recapitulate all other
aspects of CCD (Sillence et al. 1987; Otto et al. 1997).
On the one hand, since supernumerary teeth are specific
to permanent teeth in humans, it is no surprise that mice,
which possess solely primary teeth, lack this symptom.
On the other hand, the lack of short stature has thus
far been regarded to suggest that the skeletal growth in
mice could generally be more resistant to Runx2 defi-
ciency than that in humans. Analogous to the taller
female patient with mutation 151fs, however, an alter-
native culprit may be lurking somewhere in the genetic
background of the Ccd model mice—C57- or C3H-re-
lated lineages have only been employed thus far (Sillence
et al. 1987; Otto et al. 1997). Indeed, Choi et al. (2001)
have recently described a suggestive observation that
male mice (C57BL/6) heterozygous for Runx2 with a C-
terminal deletion exhibit a significantly lower weight and
weight gain than the wild type, whereas the correspond-
ing female heterozygotes show normal growth. Most re-
cently, transgenic mice made conditionally or partially
deficient for PEBP2b/Cbfb have emerged as a new Ccd
model that is severely defective in bone formation for
both cleidocranial and skeletal features (Yoshida et al.,
in press).
The genotype-phenotype correlation found in the
present study appears to be somewhat different from
what has been observed in two previous large-scale
mutational studies (Quack et al. 1999; Zhou et al.
1999). Zhou et al. (1999) examined 26 sporadic and
familial cases of CCD recruited from the United States,
Canada, and Europe, and found that most mutations
resulting in premature termination in the Runt domain
produced a classic CCD phenotype, whereas three mu-
tations (R377X, T176A, and 48insC in our notation)
with considerable residual transactivation showed a
nonuniform clinical spectrum including classic and
mild CCD, as well as an isolated dental phenotype
characterized by delayed eruption of permanent teeth.
On the other hand, Quack et al. (1999) screened 42
unrelated families with CCD of different ethnic back-
grounds recruited from Europe and other continents
but were unable to find a significant genotype-phe-
notype correlation. In these families, clavicular in-
volvement was almost invariably present, but the num-
ber and presence of supernumerary teeth was highly
variable and did not correlate with either the rest of
the phenotype or the type of mutation. In both of these
studies, functional analysis of the mutations was done
on only several cases in limited aspects, and no data
were presented for height and the number of super-
numerary teeth. Thus, it is rather difficult to compare
these previous results with ours, but the apparent dis-
crepancies between the results from the three groups
could be due to differences in either the exact diag-
nostic criteria used or the genetic backgrounds among
various ethnic groups studied.
The consistent quantitative correlation found between
the number of supernumerary teeth and short staturemay
have important implications in prognosis and treatment
of CCD, although its generality remains to be established
by further studies. It has been proposed that supernu-
merary teeth in patients with CCD should be diagnosed
and removed as early as possible, because the supernu-
merary teeth will always impede normal eruption of the
permanent teeth (Jensen and Kreiborg 1992). If the type
of mutation in RUNX2 is known in advance, we could
predict the supernumerary teeth for an individual, to al-
low the early initiation of the necessary treatment. Fur-
thermore, we could predict the final height of patients
from the number of supernumerary teeth, to judge the
necessity of prospective intervention, such as a recom-
binant human-growth-hormone (hGH) therapy, for im-
provement of their height. However, there has been con-
troversy over whether the hGH therapy really improves
growth outcomes in short non–GH-deficient children, be-
cause of its prolonged and expensive treatments (Kawai
et al. 1997; Kaplowitz 2001). One major difficulty in the
resolution of this issue may be the lack of knowledge on
underlying genetic factors in most cases. Under such cir-
cumstances, it would be tempting and justifiable to per-
form prospective studies on whether the hGH therapy is
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beneficial for patients with CCD, particularly when they
have many supernumerary teeth.
In the present study, no mutation was detected in
seven families. Now that CCD has been shown poten-
tially to result from any subtle deficiency in RUNX2, it
would be interesting and important in such cases to
extend mutational screening to nonexon and regulatory
regions of the RUNX2 gene. In addition, the possibility
also remains that certain other factors known to co-
operate with RUNX2 during bone formation could be
potential targets of mutation in these patients with
CCD. In light of the aforementioned gene-targeting
studies in mice, PEBP2b in particular should be worth
looking at. Further explorations are awaited to address
all these possibilities.
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